PLoS ONE (Jan 2021)

The smoking paradox in ischemic stroke patients treated with intra-arterial thrombolysis in combination with mechanical thrombectomy-VISTA-Endovascular.

  • Anna Kufner,
  • Huma Fatima Ali,
  • Martin Ebinger,
  • Jochen B Fiebach,
  • David S Liebeskind,
  • Matthias Endres,
  • Bob Siegerink,
  • VISTA-Endovascular Collaborators

DOI
https://doi.org/10.1371/journal.pone.0251888
Journal volume & issue
Vol. 16, no. 5
p. e0251888

Abstract

Read online

BackgroundThe smoking-paradox of a better outcome in ischemic stroke patients who smoke may be due to increased efficacy of thrombolysis. We investigated the effect of smoking on outcome following endovascular therapy (EVT) with mechanical thrombectomy alone versus in combination with intra-arterial (IA-) thrombolysis.MethodsThe primary endpoint was defined by three-month modified Rankin Scale (mRS). We performed a generalized linear model and reported relative risks (RR) for smoking (adjustment for age, sex, hypertension, atrial fibrillation, stroke severity, time to EVT) in patient data stemming from the Virtual International Stroke Trials Archive-Endovascular database.ResultsAmong 1,497 patients, 740(49.4%) were randomized to EVT; among EVT patients, 524(35.0%) received mechanical thrombectomy alone and 216(14.4%) received it in combination with IA-thrombolysis. Smokers (N = 396) had lower mRS scores (mean 2.9 vs. 3.2; p = 0.02) and mortality rates (10% vs. 17.3%; pConclusionsSmokers had no clear clinical benefit from EVT that incorporates IA-thrombolysis.